Sensus Healthcare's guest appearances

Sensus Healthcare

CFO THOUGHT LEADER

Empowered Patient Podcast

IAM Podcast

Aerami Therapeutics

Bioxcel Therapeutics

Amolyt Pharma

Anixa Biosciences

Usama Malik

Matt Murphy

Robin Smith

Thomas Cowan

Rajesh Gupta

Dave Jones

Greg Miller

Travis Mickle

Justin Miller

Jeff Epstein

John Collins

OwlTail

Joseph Sardano, Founder and CEO, Sensus Healthcare presents compelling data on the effectiveness of a non-surgical alternative to Mohs surgery for treating skin cancer and keloids.  Using Superficial Radiation Therapy otherwise known as photon radiotherapy, the Sensus SRT system allows for non-invasive treatments without leaving a scar.  In the age of COVID-19, dermatologists are finding this an excellent alternative to surgery particularly to treat those over 65 with pre-existing conditions. @Sensushealth  #skincancer  #Keloid  #Mohs #SRT #COVID19 Sensushealthcare.com Download the transcript here

Joseph Sardano, Founder and CEO, Sensus Healthcare presents compelling data on the effectiveness of a non-surgical alternative to Mohs surgery for treating skin cancer and keloids.  Using Superficial Radiation Therapy otherwise known as photon radiotherapy, the Sensus SRT system allows for non-invasive treatments without leaving a scar.  In the age of COVID-19, dermatologists are finding this an excellent alternative to surgery particularly to treat those over 65 with pre-existing conditions. @Sensushealth  #skincancer  #Keloid  #Mohs #SRT #COVID19 <a href="http://Sensushealthcare.com" rel="noopener nofollow" target="_blank">Sensushealthcare.com</a> <a href="http://empoweredpatientradio.com/superficial-radiation-therapy-strong-alternative-to-mohs-surgery-for-skin-cancer-with-joseph-sardano-sensus-healthcare-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Superficial Radiation Therapy Strong Alternative to Mohs Surgery for Skin Cancer with Joseph Sardano Sensus Healthcare

Arthur Levine

Back in 2014, shortly after Arthur Levine first stepped into the CFO office at Sensus Healthcare, the fast-growing medical device company hit a sizable speed bump. A growing number of future Sensus customers were putting their purchases on hold as uncertainty around insurance reimbursements grew in relation to a review being conducted by The Centers for Medicare &amp; Medicaid Services. In order to quickly ease the company’s hefty appetite for cash, Levine and Sensus management executed a sizable layoff largely impacting the company’s sales team–while for the time being the healthcare company opted to leave its research and development team untouched. Ultimately, reimbursements for Sensus offerings remained in place and product demand surged, allowing its 2015 revenues to jump 77 percent. Such news could not have been better timed for an initial public offering, a notion upon which Sensus acted in early 2016. “We became one of the first companies to complete an IPO in 2016. Actually, we were the only Florida-based company to go public on a major exchange that year,” explains Levine, who had helped to restore the company’s sales function by green-lighting a flurry of new sales hires in 2015. “I like the challenge of turning companies around,” says Levine, who quickly adds: “I also like periods of stability and a little less stress.” –Jack Sweeney    NOW SUBSCRIBE The Quarterly Digest of CFO Strategic Insight-  http://bit.ly/2Wfv291

Back in 2014, shortly after Arthur Levine first stepped into the CFO office at Sensus Healthcare, the fast-growing medical device company hit a sizable speed bump. A growing number of future Sensus customers were putting their purchases on hold as uncertainty around insurance reimbursements grew in relation to a review being conducted by The Centers for Medicare &amp; Medicaid Services. In order to quickly ease the company’s hefty appetite for cash, Levine and Sensus management executed a sizable layoff largely impacting the company’s sales team–while for the time being the healthcare company opted to leave its research and development team untouched. Ultimately, reimbursements for Sensus offerings remained in place and product demand surged, allowing its 2015 revenues to jump 77 percent. Such news could not have been better timed for an initial public offering, a notion upon which Sensus acted in early 2016. “We became one of the first companies to complete an IPO in 2016. Actually, we were the only Florida-based company to go public on a major exchange that year,” explains Levine, who had helped to restore the company’s sales function by green-lighting a flurry of new sales hires in 2015. “I like the challenge of turning companies around,” says Levine, who quickly adds: “I also like periods of stability and a little less stress.” –Jack Sweeney    NOW SUBSCRIBE The Quarterly Digest of CFO Strategic Insight-  <a href="http://bit.ly/2Wfv291" rel="nofollow" target="_blank">http://bit.ly/2Wfv291</a>

491: When the Virtues of Organic Growth Trump M&A | Arthur Levine, CFO, Sensus Healthcare